![Laurent Lavigne du Cadet](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Laurent Lavigne du Cadet
Direttore Finanziario/CFO presso NeuroCytonix, Inc.
Posizioni attive di Laurent Lavigne du Cadet
Società | Posizione | Inizio | Fine |
---|---|---|---|
NeuroCytonix, Inc.
![]() NeuroCytonix, Inc. BiotechnologyHealth Technology NeuroCytonix, Inc. is an emerging biotechnology company based in Rockville, MD. Dr. J. Roberto Trujillo, an MD and PhD from Harvard University, has been a leader in clinical and basic neuroscience research for brain regeneration technology for the past 25 years. NeuroCytonix develops and exploits transformational medical technologies for the regeneration of the nervous system. The company's core technology, the NeuroCytoTron, utilizes non-invasive, safe, tissue engineering technology that stimulates proteins aiding in the regeneration of brain cells. The company's technology and related protocols include stroke, autism, cerebral palsy, and neurological consequences of traumatic brain injury (TBI) and COVID-19. The company was founded in 2017 by J. Roberto Trujillo, who is also the CEO. | Direttore operativo | - | - |
Direttore Finanziario/CFO | - | - |
Storia della carriera di Laurent Lavigne du Cadet
Statistiche
Distribuzione geografica
Stati Uniti | 2 |
Posizioni
Chief Operating Officer | 1 |
Director of Finance/CFO | 1 |
Settori
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
NeuroCytonix, Inc.
![]() NeuroCytonix, Inc. BiotechnologyHealth Technology NeuroCytonix, Inc. is an emerging biotechnology company based in Rockville, MD. Dr. J. Roberto Trujillo, an MD and PhD from Harvard University, has been a leader in clinical and basic neuroscience research for brain regeneration technology for the past 25 years. NeuroCytonix develops and exploits transformational medical technologies for the regeneration of the nervous system. The company's core technology, the NeuroCytoTron, utilizes non-invasive, safe, tissue engineering technology that stimulates proteins aiding in the regeneration of brain cells. The company's technology and related protocols include stroke, autism, cerebral palsy, and neurological consequences of traumatic brain injury (TBI) and COVID-19. The company was founded in 2017 by J. Roberto Trujillo, who is also the CEO. | Health Technology |